Menopausal women with chronic hepatitis C
Conditions
Interventions
Patients are randomly separated into two treatment groups: raloxifene plus pegylated interferon alpha plus ribavirin treatment as the current standard of care (SOC) and SOC only groups from 2010 to 20
Sponsors
Department of General Internal Medicine, Kyushu University Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: All patients are menopausal women with chronic hepatitis C and osteoporosis, and satisfy the following criteria: (1) positivity for hepatitis C virus (HCV) antibody and HCV RNA (2) a history of an increased alanine aminotransferase level for over six months.
Exclusion criteria
Exclusion criteria: Exclusion criteria for the study were: (1) positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen; (2) clinical or biochemical evidence of hepatic decompensation; (3) excessive active alcohol consumption (> 60 g/day converted into ethanol) or drug abuse; (4) suspected hepatocellular carcinoma at entry; or (5) treatment with antiviral or immunosuppressive agents prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Virological response was evaluated by Abbott RealTime PCR assay. | — |
Countries
Japan
Contacts
Public ContactNorihiro Furusyo
Kyushu University Hospital Department of General Internal Medicine
Outcome results
None listed